Form 4: Charles River Laboratories Director Acquires Shares and Stock Options

Director Richard F. Wallman reports acquisition of common stock and stock options in Charles River Laboratories.

Summary

• Richard F. Wallman, a director of Charles River Laboratories International, Inc., filed a Form 4 detailing changes in beneficial ownership.
• On May 13, 2024, Wallman acquired 559 shares of common stock at $228.41 per share and an additional 460 shares of common stock at $228.41 per share.
• Wallman also acquired 1,311 stock options with an exercise price of $228.41, exercisable starting May 13, 2025, or the day before the next annual meeting, and expiring on May 13, 2034.
• Following these transactions, Wallman directly owns 23,547 shares of common stock and 1,311 stock options.
• Wallman also indirectly owns 1,000 shares of common stock through his wife.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it is a standard disclosure of a director's stock transactions. The acquisitions could be seen as slightly positive, but it's not a major event.

Positives

• The director's acquisition of shares and stock options could be interpreted as a positive signal, indicating confidence in the company's future performance.
• The grant of restricted stock units in lieu of director service fees aligns the director's interests with those of the shareholders.

Future Outlook

The restricted stock units and stock options vest upon the earlier of 5/13/2025 or the business day prior to the Company's next annual meeting of shareholders.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future actions of key individuals within the company.

Stakeholder Impact

• The director's stock acquisitions may have a minor positive impact on shareholder sentiment.

Key Dates